Commercial Strategy
ELARA is committed to rapid preclinical development
and validation of its lead series. Our goal is to further enhance
the development of our lead series through a combination of partnering
with biotech-pharma and equity capital investment. Our early preclinical
lead series are available for partnering or out-licensing. An
essential prerequisite is that such potential partners and investors
share our sense of urgency and have a proven track record of progressing
discovery projects into development. They are expected to complement
ELARA’s capabilities and network.
investors
Elara was founded in July of 2006 with seed capital
from EMBL Ventures. The intellectual properties was licensed exclusively
to ELARA by EMBL- EM.
Contact ELARA:
Dr Joe Lewis, CEO
Elara Pharmaceuticals GmbH
Boxbergring 107
69126 Heidelberg
Germany
Email: j.lewis[at]elarapharma.com
Tel: +49 (0)6221 3878935
Mobile: +49(0)1608438979
Fax: +49 (0)6221 3878971
Web: www.elarapharma.com |
Contact EMBL Ventures:
Dr. Christof Antz
EMBL Ventures GmbH
Boxbergring 107
69126 Heidelberg
Germany
Email: antz[at]embl-ventures.com
Tel: +49 (0)6221 389330
Fax: +49 (0)6221 3893311
Web: www.embl-ventures.com |